Form 4: Herbalife CFO Granted 45,195 Stock Appreciation Rights

Herbalife's Chief Financial Officer, John DeSimone, was granted 45,195 Stock Appreciation Rights with an exercise price of $10.51.

Summary

• John DeSimone, Chief Financial Officer of Herbalife Ltd. (HLF), was granted 45,195 Stock Appreciation Rights (SARs).
• The SARs were granted on February 25, 2026, under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
• Each SAR has an exercise price of $10.51.
• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, contingent on continued service.
• The expiration date for these SARs is February 25, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive practices that align management's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of Stock Appreciation Rights aligns the Chief Financial Officer's incentives with shareholder value creation, as SARs only have value if the stock price increases above the exercise price.
• The long vesting schedule (over three years) encourages long-term commitment and retention of a key executive.

Negatives

• The grant of SARs represents potential future dilution if exercised, although SARs are typically settled in cash or net shares, limiting the direct impact on share count compared to full stock options.

Risks

• The value of the SARs is entirely dependent on the future stock performance of Herbalife Ltd. above the $10.51 exercise price; if the stock price does not appreciate, the SARs may expire worthless.
• The vesting is subject to continued service, meaning the executive must remain employed to realize the benefit, which is a standard risk for incentive compensation.

Future Outlook

The vesting schedule for the Stock Appreciation Rights extends through February 2029, indicating a long-term incentive structure tied to the company's future performance and the executive's continued service.

Industry Context

StockSavvy.ai notes that equity grants, such as Stock Appreciation Rights, are a common component of executive compensation packages across various industries, particularly in consumer goods and direct selling, to incentivize performance and align management interests with shareholders. This grant is consistent with typical practices for retaining and motivating senior leadership.

Comparison to Industry Standards

• The grant of SARs to a Chief Financial Officer is a standard practice in publicly traded companies, comparable to compensation structures at peers like Nu Skin Enterprises (NUS) or USANA Health Sciences (USNA), which also utilize equity-based incentives to retain key executives.
• The vesting schedule of three annual increments is typical for long-term incentive plans, ensuring sustained executive commitment over several years, aligning with best practices seen in companies across the S&P 500.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation, as the SARs gain value only if the stock price rises. Minor potential for future dilution if SARs are settled in shares.
• Employees: The grant to a key executive may signal stability in leadership and a commitment to long-term incentive programs.

Next Steps

• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (grant of SARs) and does not contain information that would fundamentally alter the investment thesis for Herbalife Ltd. It is a standard practice to align executive incentives with shareholder value, and while generally positive, it does not present new material information warranting a change in an existing 'hold' position.

Keywords

Herbalife, HLF, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, Equity Grant, John DeSimone